Ko Nakajo

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo et al. · The Journal of Dermatology · 2016 · 190 citations · Full text

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Yukari Okubo, Tomotaka Mabuchi, Keiji Iwatsuki et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 62 citations · Full text

Long‐term efficacy and safety results from an open‐label phase <scp>III</scp> study (<scp>UNCOVER</scp>‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

Yoshinori Umezawa, Hitoe Torisu‐Itakura, Yoji Morisaki et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 35 citations · Full text

Transmissibility of asymptomatic COVID-19: Data from Japanese clusters

Ko Nakajo, Hiroshi Nishiura · International Journal of Infectious Diseases · 2021 · 27 citations · Full text

Efficacy and safety of 40 mg or 60 mg duloxetine in <scp>J</scp>apanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study

Hitoshi Yasuda, Nigishi Hotta, Masato Kasuga et al. · Journal of Diabetes Investigation · 2015 · 25 citations · Full text